Rocket Pharmaceuticals’ KRESLADI Review Extended by FDA

Rocket Pharmaceuticals (RCKT) has released an update.

Rocket Pharmaceuticals, Inc. has announced a three-month extension by the FDA for the Priority Review of KRESLADI™, their treatment for severe Leukocyte Adhesion Deficiency-I. This delay until June 30, 2024, allows the FDA to review additional details regarding the drug’s Chemistry, Manufacturing, and Controls, submitted by Rocket to address the agency’s requests for more information.

For further insights into RCKT stock, check out TipRanks’ Stock Analysis page.